Evidence map›Paper›PMID 41196294›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2026

Botulinum toxin for chronic migraine.

Lejla Paracka, Dirk Dressler

Abstract readReview
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lejla ParackaMovement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. paracka.lejla@mh-hannover.de.
Dirk DresslerMovement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic migraine (CM) is a common primary headache occurring on 15 or more days per month and for more than three months. It presents a considerable therapeutic challenge. Botulinum toxin (BoNT) has emerged as a promising treatment for CM, particularly in patients unresponsive to standard pharmacological therapy or experiencing adverse effects. Its therapeutic benefit is based on blocking the release of nociceptive neuropeptides modulating pain pathways. Clinical efficacy and safety of BoNT have been demonstrated in multiple randomized controlled CM trials showing a significant reduction of headache frequency. This review provides an overview of efficacy and safety of BoNT for CM.

Indexed as

Botulinum ToxinsBotulinum Toxins, Type AMigraine DisordersAnimalsChronic DiseaseHumansBotulinum ToxinsBotulinum Toxins, Type ABotulinum toxinChronic migraineEfficacyReviewSafety

Identifiers

PMID41196294
PMCPMC13331845

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.